Albany Molecular Research (NASDAQ: AMRI) was upgraded by Zacks Investment Research from an “underperform” rating to a “neutral” rating in a report issued on Saturday.
Separately, analysts at Sterne Agee reiterated a “buy” rating on shares of Albany Molecular Research in a research note to investors on Monday, December 5th. They now have a $7.00 price target on the stock. Analysts at Citigroup (NYSE: C) downgraded shares of Albany Molecular Research to a “sell” rating in a research note to investors on Wednesday, November 30th.
Albany Molecular Research, Inc. (AMRI) provides scientific services, technologies and products. The Company’s core business consists of a fee-for-service contract services platform encompassing drug discovery, development and manufacturing services, and a separate, technology division consisting of technology investments, internal drug discovery and generic active pharmaceutical ingredient product development. With locations in the United States, Europe and Asia, the Company provides customers with a range of services, technologies and cost models. Its customers include pharmaceutical companies and biotechnology companies and, to a limited extent, agricultural companies, fine chemical companies, contract chemical manufacturers, government research entities and non-profit organizations. In June 2010, it acquired Hyaluron Inc.
Albany Molecular Research traded up 1.30% on Friday, hitting $3.11. Albany Molecular Research has a 52-week low of $2.08 and a 52-week high of $5.67. The stock has a 50-day moving average of $2.74 and a 200-day moving average of $3.32. The company’s market cap is $93.4 million.